{"id":"W4281631797","doi":"10.1200/jco.2022.40.16_suppl.8006","title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Toxicity; Cohort; Antibody; Oncology; Immunology; Cancer; Chimeric antigen receptor; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002955602,0.001795235,0.001691545,0.0004062354,0.0006829622,0.001070467,0.0009600121,0.001612549,0.003244813],"category_scores_gemma":[0.001895891,0.0005231887,0.001268304,0.0004175738,0.0008854788,0.001025266,0.0005114395,0.003330826,0.000927491],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001264323,"about_ca_system_score_gemma":0.001947082,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009983706,"about_ca_topic_score_gemma":0.002400196,"domain_scores_codex":[0.9991009,0.0005409258,0.00003917231,0.0001221286,0.00007855235,0.0001182851],"domain_scores_gemma":[0.9988305,0.0002437028,0.000230557,0.00009965942,0.00008938288,0.0005061594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7694243,0.0570309,0.01370188,0.0006539742,0.001440444,0.0007230929,0.0005258832,0.003585227,0.04927399,0.0002980725,0.009091565,0.09425072],"study_design_scores_gemma":[0.5243741,0.4356801,0.02502524,0.00006137854,0.0008531975,0.000809231,0.00006726991,0.002086184,0.006273051,0.0004199453,0.004301486,0.00004889083],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882793,0.00167756,0.0009079591,0.0007426974,0.00007525203,0.003056366,0.00281324,0.0001147728,0.002332776],"genre_scores_gemma":[0.9839121,0.001198944,0.002148124,0.001575409,0.0001998737,0.003285376,0.005769591,0.00006800815,0.001842493],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003244813,"threshold_uncertainty_score":0.0156309,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09750823413975031,"score_gpt":0.4644746690344346,"score_spread":0.3669664348946843,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}